• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Packaging Technology

    Elemental Impurities: The Time Has Come

    Continuous vs. Batch Production

    2018: The evolution of pharmaceutical packaging

    Formulation Development Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    InClinica Names BD Manager

    SCHOTT Introduces syriQ BioPure

    Heritage Pharma Makes Leadership Changes

    JLL and Water Street Acquire Triplefin

    WuXi AppTec Opens Laboratory Testing Facility in NJ
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Opens Laboratory Testing Facility in NJ

    Arcinova Receives £1.5M Innovate UK Grant

    Vetter Welcomes Illinois Governor

    Sterling Pharma Invests £6M To Expand Offerings

    PhoenixMD, STA Enter Manufacturing Agreement
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    INTERPHEX: Adents Showcases Cloud-Based Serialization Solution

    Almac Group Expands Packaging Capabilities

    Catalent Bolsters Clinical Supply Capabilities

    West, Stevanato Group Enter Ompi EZ-fill Alliance

    Pharmaceutical Packaging Technology
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    WuXi AppTec Opens Laboratory Testing Facility in NJ

    ICON, Intel Enter Pharma Analytics Platform Pact

    AMRI Renews NIH Contract

    Sterling Pharma Invests £6M To Expand Offerings

    PhoenixMD, STA Enter Manufacturing Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Blockchain: The Next Big Trend in BioPharma?

    Emergent Completes Market Authorization

    Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle: ICH Q12

    LSNE Expands Capabilities and QC Laboratory Space

    Evotec Launches Drug Development Service
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Apex Graphics Inc.

    Rockledge Pharmaceutical Manufacturing, LLC

    Symbiosis Pharmaceutical Services

    Adaptive Clinical Systems

    Avid Bioservices, Inc.
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Bio News & Views Interview

    Related CONTENT
    • Tandem Labs Offers GLP Assay Services
    • Tandem Labs Acquires PharmaKD
    • Tandem Adds Discovery Capacity
    • BASi
    • PPD Appoints Biomarker Lab Director
    Gil Roth11.03.06

    Bio News & Views Interview



    An online exclusive interview with Dr. James Jersey



    by Gil Roth



    In September 2006, Tandem Labs acquired PharmaKD, a Boston-based, mass spectrometry-oriented provider of drug metabolite and biomarker identification services. With the acquisition, Tandem obtained proprietary informatics that can "reduce the difficulty, complexity, and time-consuming nature of developing and launching a drug to market," according to the company. This included MarkerScan, a biomarker discovery and screening process to "efficiently identify potential biomarkers that can be used to increase the understanding of disease, diagnosis, and predictive models as well as drug compound safety, efficacy, and side-effect profiles."

    Dr. James Jersey was named vice president and general manager of the new Tandem Labs - New England. From 1996 to 2004, Dr. Jersey founded and managed the rapid growth of a contract, fee-for-service bioanalytical services division within Primedica Corp., which was acquired by Charles River Laboratories in March 2001. While at Charles River Labs, he established and served as president of a new fee-for-service contract proteomic research services company in 2003. He also served as founder, chief technical officer, and senior scientist of the Bioanalytical Division within Triangle Laboratories.

    We spoke a week after his new appointment to discuss the acquisition and the current state of the biomarker field.

    Contract Pharma: Where was PharmaKD prior to this acquisition by Tandem?

    Dr. Jersey: PharmaKD was an existing business. It was approximately two years old at the time of the acquisition. In that span, we were very focused on biomarker discovery, or identification. This was work where we, for a fee, did discovery work for potential biomarkers.

    PharmaKD worked very closely with sponsors to understand what the questions were, and to develop an experimental approach to get the best chance of success. We were using mass spectrometry and liquid chromatography together with some proprietary data management tools to make the process as efficient as possible.

    So the value-add comes in with the use of proprietary systems?

    Yes. These experiments yield tremendous volumes of data, so the ability to manage that dataset effectively is a critical measure of success.

    How did this service attract Tandem's attention?

    I think it was very complimentary with what they do. Tandem worked extensively -- but not exclusively -- in the regulated bioanalysis market. They did some discovery bioanalysis, but what we were doing at PharmaKD was more qualitative in nature, identifying potential biomarkers, rather than quantifying them. Our technology was complimentary.

    PharmaKD also performed drug metabolism identification. That is, knowing what the metabolites are, what can we do to improve the pharmacokinetics for a compound? The same informatic tools that we use in biomarkers are also applicable in drug metabolism identification. That complements well what Tandem was doing.

    Third reason for their interest was that PharmaKD is based in the Massachusetts area, which is one of the Pharma R&D hubs.

    What's your definition of a biomarker?

    Now, "biomarker" is a widely used term, interpreted in many different ways . . .

    I would go back to the FDA's Critical Path and use their definition. It's a molecule -- large or small -- that in some way is indicative or predictive of potential efficacy or adverse events, safety issues, and the like. The FDA has a wealth of information on its site.

    I think it's still very much a maturing science. It can be a discrete molecule. Some biomarkers have been around for a very long time. A biomarker can consist of panels of compounds that collectively have predictive power. Conversely, it can be patterns where you don't necessarily know the identity of each constituent. So it's a pretty inclusive definition we're looking at, and it's my belief that we're still very early on.

    I think if you look at the pharma R&D productivity, efficiency, return on dollar, there's clearly a role that biomarkers are going to play in improving the process. Ultimately, they're going to be tools for making better decisions.

    In terms of making a fail-fast decision?

    I think that's correct. That's the most commercially developed direction. But there will also be markers of efficacy. I think there'll be markers used in diagnostics, personalized medicine. "Who's going to be a responder, and who's not going to be a responder?" So they're not always going to be adverse, fail-fast markers; there'll be positive benefits as well.

    Still, I think fail-fast will be the first significant application. There are still too many compounds that are failing late, at costly stages in development. That's the most fertile ground to plow at this point.

    What advances have occurred in biomarkers in recent years?

    The biggest advancement is the understanding within the marketplace of the importance of biomarkers and how difficult it's going to be to have validated ones. It's very easy to have potential biomarkers, but to actually validate that biologically is another exercise.

    In the beginning of the genomics and proteomics wave, everyone was under the belief that there was going to be an instantaneous revolution. Expectations exceeded the technology's ability to deliver. It's not going to happen overnight. So I think the biggest advancement is understanding what rate of development is going to be for these contributions.

    Technologically, I don't know if there have been any huge advances or breakthroughs; it's more about the community getting a conceptual grasp of what's going on.

    Are we looking at a period of incremental improvements, or is there room for a major leap?

    I think we're poised for incremental improvement. I don't see a differentiating technology yet.

    So there's no J. Craig Venter out there to come up with a shotgun method?

    You know, since the mid-1990s, there's been a quantum increase in information management, computational  power, biology, ADME, combi-chem, high throughput screening. I think they've actually done a good job in improving drug compound failures due to pharmacokinetics issues. That's actually gotten better. But look at the investment and time-span that's gone by.

    These tools make it easy to generate information, but not necessarily knowledge. That's key right now. We can generate plenty of information, but what does it mean? Was the experiment designed properly? I think we've entered the golden age of biology. That's where the winners and losers are going to be determined. It's all about target assessment, target validation.

    Who's out in front?

    I think Pfizer's doing a good job. There's a lot of emphasis toward finding markers of toxicology, to avoid adverse events and safety issues. Lots of emphasis on the preclinical side. It's along the lines of killing the bad compound quickly, that fail-fast concept.

    I don't think it's reasonable to expect rapid change. I just don't think it happens that way. There are regulatory issues. I mean, who wants to be first? There's career-risk in that.

    There's no lottery mentality when it comes to biomarkers. It's going to take a lot of people rolling up their sleeves and doing hard work for a number of years for this to bear fruit. No instant gratification here.
    Related Searches
    • Development
    • bioanalysis
    • contract pharma
    • Bioanalytical
    Suggested For You
    Overcoming Preclinical Drug Development Hurdles Overcoming Preclinical Drug Development Hurdles
     Vantage Consulting is First Systems Integrator to Join PBOA Vantage Consulting is First Systems Integrator to Join PBOA
    Nimbus Therapeutics, Charles River in Strategic R&D Alliance Nimbus Therapeutics, Charles River in Strategic R&D Alliance
    Whither Washington? Whither Washington?
    The Good, the Bad, and the Donald The Good, the Bad, and the Donald
    Like the Temperature, It Feels Like Deal Activity is Heating Up Like the Temperature, It Feels Like Deal Activity is Heating Up
    Financial Report: Charles River Labs Financial Report: Charles River Labs
    Recap of Notable Recent CRO Transactions Recap of Notable Recent CRO Transactions
    PPD Appoints Biomarker Lab Director PPD Appoints Biomarker Lab Director
    BASi BASi
    Tandem Adds Discovery Capacity Tandem Adds Discovery Capacity
    Tandem Labs Acquires PharmaKD Tandem Labs Acquires PharmaKD
    Tandem Labs Offers GLP Assay Services Tandem Labs Offers GLP Assay Services

    Related Online Exclusives

    • Bio News | Industry News | Validation
      Blockchain: The Next Big Trend in BioPharma?

      Blockchain: The Next Big Trend in BioPharma?

      Accenture Life Sciences' Carly L. Guenther shares her thoughts on the future of blockchain in supply chain management
      Betsy Louda, Associate Editor 04.13.18

    • Biologic Sample Management in R&D

      Biologic Sample Management in R&D

      Vyas of PAREXEL discusses the significance of biologic samples, sample management challenges and the regulatory implications
      Kristin Brooks, Managing Editor 02.15.18

    • Bio News | Industry News
      Weill Cornell Joins the TriNetX Network

      Weill Cornell Joins the TriNetX Network

      The move makes their total patient population of over two million available for query through the platform
      02.08.18


    • Inspections | QA/QC | Regulatory Affairs | Serialization
      2015 Contracting & Outsourcing Wrap-up

      2015 Contracting & Outsourcing Wrap-up

      A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions
      Kristin Brooks, Contract Pharma 09.30.15

    • Capsules | Excipients | GMPs/GCPs | Industry News | Inspections | Process Development | Regulatory Affairs | Solid Dosage/Semi-solids

      Molecular Profiles Hosts Bioavailability Event

      Biannual event attracts scientists, executives
      Gil Roth 02.11.14

    • CRO News | GMPs/GCPs | Inspections | Process Development | Regulatory Affairs

      PAREXEL Creates Customized Biopharm Unit

      Q&A with Ubavka DeNoble, M.D. about small and mid-size company needs
      Kristin Brooks 11.06.13


    • WIL Research Acquires Ricerca Lyon

      CEO David Spaight explains geographic, capacity play
      Gil Roth 08.26.13

    • Capsules | Collaborations & Alliances | Excipients | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Parenterals | Process Development | Scale-up/Technology Transfer | Solid Dosage/Semi-solids | Vials
      Halo/Altus Q&A

      Halo/Altus Q&A

      Halo's CEO discusses his recent formulation partnership
      Gil Roth 06.12.13

    • Collaborations & Alliances | CRO News | GMPs/GCPs | Process Development
      Quintiles Q&A

      Quintiles Q&A

      Discussing a new partnership with Merck Serono
      Kristin Brooks 06.05.13


    • Capsules | Cleaning Validation | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Process Development | Process Validation | QA/QC | Solid Dosage/Semi-solids | Validation | Vials

      Manufacturing Equipment Trends

      Industry perspective from suppliers and manufacturers
      Kristin Brooks, Associate Editor 03.07.12

    • Bio News | Process Development

      BIO 2011 Wrapup

      Video interviews from the world's biggest biotech show
      Gil Roth 07.20.11

    • GMPs/GCPs | Logistics | Serialization | Supply Chain

      DIA Wrapup

      News and video from the 47th annual DIA Meeting
      Kristin Brooks 07.13.11

    • Ricerca Interview

      Ricerca CEO Ian Lennox discusses the acquisition of MDS Pharma Services
      Kristin Brooks 04.08.10

    • Commentary on CRL accident

      Shame! A commentary by Steve Snyder [EDITOR'S NOTE: Mr. Snyder's commentary does not necessarily reflect the opinions of Contract Pharma LLC or any of its staff, but as the editor of this magazine and website, I decided that his opinion des…
      Steve Snyder 08.18.08

    Breaking News
    • InClinica Names BD Manager
    • SCHOTT Introduces syriQ BioPure
    • Heritage Pharma Makes Leadership Changes
    • JLL and Water Street Acquire Triplefin
    • WuXi AppTec Opens Laboratory Testing Facility in NJ
    View Breaking News >
    CURRENT ISSUE

    April 2018

    • Pharmaceutical Packaging Technology
    • Elemental Impurities: The Time Has Come
    • Continuous vs. Batch Production
    • 2018: The evolution of pharmaceutical packaging
    • Formulation Development Trends
    • Changing Dynamics: The CDMO market in focus
    • Contract BioManufacturing in China: Creating a New Segment
    • View More >

    Copyright © 2018 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.